197 related articles for article (PubMed ID: 33046500)
1. Efficacy of Telavancin in Comparison to Linezolid in a Porcine Model of Severe Methicillin-Resistant Staphylococcus aureus Pneumonia.
Battaglini D; Motos A; Li Bassi G; Yang H; Pagliara F; Yang M; Aguilera Xiol E; Meli A; Bobi J; Frigola G; Senussi T; Idone F; Travierso C; Chiurazzi C; Fernandez-Barat L; Rigol M; Ramirez J; Pelosi P; Chiumello D; Antonelli M; Nicolau DP; Bringue J; Artigas A; Guerrero L; Soy D; Torres A
Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33046500
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of telavancin in comparison with linezolid on endotracheal tube biofilm in pigs with methicillin-resistant Staphylococcus aureus pneumonia.
Kiarostami K; Fernández-Barat L; Battaglini D; Motos A; Bueno-Freire L; Soler-Comas A; Bassi GL; Torres A
Int J Antimicrob Agents; 2024 Feb; 63(2):107052. PubMed ID: 38072170
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
Crandon JL; Kuti JL; Nicolau DP
Antimicrob Agents Chemother; 2010 Dec; 54(12):5115-9. PubMed ID: 20837760
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of linezolid compared to vancomycin in an experimental model of pneumonia induced by methicillin-resistant Staphylococcus aureus in ventilated pigs.
Martinez-Olondris P; Rigol M; Soy D; Guerrero L; Agusti C; Quera MA; Li Bassi G; Esperatti M; Luque N; Liapikou M; Filella X; Marco F; de la Bellacasa JP; Torres A
Crit Care Med; 2012 Jan; 40(1):162-8. PubMed ID: 21926613
[TBL] [Abstract][Full Text] [Related]
5. Comparative in vivo efficacies of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model.
Tessier PR; Keel RA; Hagihara M; Crandon JL; Nicolau DP
Antimicrob Agents Chemother; 2012 May; 56(5):2342-6. PubMed ID: 22354302
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: studies with a rabbit model.
Yin LY; Calhoun JH; Thomas TS; Wirtz ED
J Antimicrob Chemother; 2009 Feb; 63(2):357-60. PubMed ID: 19060292
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria.
Hegde SS; Reyes N; Wiens T; Vanasse N; Skinner R; McCullough J; Kaniga K; Pace J; Thomas R; Shaw JP; Obedencio G; Judice JK
Antimicrob Agents Chemother; 2004 Aug; 48(8):3043-50. PubMed ID: 15273119
[TBL] [Abstract][Full Text] [Related]
8. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens.
Rubinstein E; Lalani T; Corey GR; Kanafani ZA; Nannini EC; Rocha MG; Rahav G; Niederman MS; Kollef MH; Shorr AF; Lee PC; Lentnek AL; Luna CM; Fagon JY; Torres A; Kitt MM; Genter FC; Barriere SL; Friedland HD; Stryjewski ME;
Clin Infect Dis; 2011 Jan; 52(1):31-40. PubMed ID: 21148517
[TBL] [Abstract][Full Text] [Related]
9. Linezolid versus vancomycin for nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus in the elderly: A retrospective cohort analysis: Effectiveness of linezolid in the elderly.
Takada H; Hifumi T; Nishimoto N; Kanemura T; Yoshioka H; Okada I; Kiriu N; Inoue J; Koido Y; Kato H
Am J Emerg Med; 2017 Feb; 35(2):245-248. PubMed ID: 27832976
[TBL] [Abstract][Full Text] [Related]
10. Activity of Telavancin against Staphylococcus aureus Isolates, Including Those with Decreased Susceptibility to Ceftaroline, from Cystic Fibrosis Patients.
Roch M; Varela MC; Taglialegna A; Rose WE; Rosato AE
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914961
[TBL] [Abstract][Full Text] [Related]
11. Health economic evaluation of patients treated for nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus: secondary analysis of a multicenter randomized clinical trial of vancomycin and linezolid.
Niederman MS; Chastre J; Solem CT; Wan Y; Gao X; Myers DE; Haider S; Li JZ; Stephens JM
Clin Ther; 2014 Sep; 36(9):1233-1243.e1. PubMed ID: 25066668
[TBL] [Abstract][Full Text] [Related]
12. New therapy options for MRSA with respiratory infection/pneumonia.
Ramirez P; Fernández-Barat L; Torres A
Curr Opin Infect Dis; 2012 Apr; 25(2):159-65. PubMed ID: 22248980
[TBL] [Abstract][Full Text] [Related]
13. European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid.
Chastre J; Blasi F; Masterton RG; Rello J; Torres A; Welte T
Clin Microbiol Infect; 2014 Apr; 20 Suppl 4():19-36. PubMed ID: 24580739
[TBL] [Abstract][Full Text] [Related]
14. Linezolid limits burden of methicillin-resistant Staphylococcus aureus in biofilm of tracheal tubes.
Fernández-Barat L; Ferrer M; Sierra JM; Soy D; Guerrero L; Vila J; Li Bassi G; Cortadellas N; Martínez-Olondris P; Rigol M; Esperatti M; Luque N; Saucedo LM; Agustí C; Torres A
Crit Care Med; 2012 Aug; 40(8):2385-9. PubMed ID: 22622402
[TBL] [Abstract][Full Text] [Related]
15. Effective Antimicrobial Stewardship Strategies for Cost-effective Utilization of Telavancin for the Treatment of Patients With Hospital-acquired Bacterial Pneumonia Caused by Staphylococcus aureus.
McKinnell JA; Corman S; Patel D; Leung GH; Gordon LM; Lodise TP
Clin Ther; 2018 Mar; 40(3):406-414.e2. PubMed ID: 29454592
[TBL] [Abstract][Full Text] [Related]
16. Pharmacotherapy for methicillin-resistant Staphylococcus aureus nosocomial pneumonia.
Segarra-Newnham M; Church TJ
Ann Pharmacother; 2012 Dec; 46(12):1678-87. PubMed ID: 23232021
[TBL] [Abstract][Full Text] [Related]
17. Telavancin: a review of its use in patients with nosocomial pneumonia.
Scott LJ
Drugs; 2013 Nov; 73(16):1829-39. PubMed ID: 24190596
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus.
Reyes N; Skinner R; Kaniga K; Krause KM; Shelton J; Obedencio GP; Gough A; Conner M; Hegde SS
Antimicrob Agents Chemother; 2005 Oct; 49(10):4344-6. PubMed ID: 16189117
[TBL] [Abstract][Full Text] [Related]
19. Nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus treated with linezolid or vancomycin: A secondary economic analysis of resource use from a Spanish perspective.
Rello J; Nieto M; Solé-Violán J; Wan Y; Gao X; Solem CT; De Salas-Cansado M; Mesa F; Charbonneau C; Chastre J
Med Intensiva; 2016 Nov; 40(8):474-482. PubMed ID: 27061776
[TBL] [Abstract][Full Text] [Related]
20. In Vitro Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant Staphylococcus aureus with and without Prior Vancomycin Exposure.
Thabit AK; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2016 Jan; 60(1):222-8. PubMed ID: 26482306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
